Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by James Hambro & Partners LLP

James Hambro & Partners LLP trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 244,809 shares of the medical equipment provider’s stock after selling 4,980 shares during the quarter. Intuitive Surgical comprises about 5.0% of James Hambro & Partners LLP’s portfolio, making the stock its 10th biggest position. James Hambro & Partners LLP owned approximately 0.07% of Intuitive Surgical worth $120,276,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Creekmur Asset Management LLC increased its position in Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares in the last quarter. Ridgewood Investments LLC bought a new stake in shares of Intuitive Surgical during the second quarter valued at approximately $26,000. Delos Wealth Advisors LLC increased its holdings in shares of Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Godsey & Gibb Inc. lifted its holdings in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares in the last quarter. Finally, LRI Investments LLC acquired a new stake in Intuitive Surgical in the 1st quarter valued at $30,000. 83.64% of the stock is currently owned by institutional investors.

Insider Transactions at Intuitive Surgical

In related news, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the transaction, the director now owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $446.60, for a total value of $167,921.60. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,458,979.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Mizuho boosted their price objective on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday. Royal Bank of Canada raised their target price on Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a report on Friday. Wells Fargo & Company upped their price target on Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Piper Sandler reissued an “overweight” rating and set a $538.00 target price (up previously from $495.00) on shares of Intuitive Surgical in a research report on Friday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock traded down $2.00 during trading hours on Monday, reaching $519.15. The company had a trading volume of 445,338 shares, compared to its average volume of 1,474,347. The firm has a market cap of $184.14 billion, a PE ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $523.34. The business has a fifty day simple moving average of $483.85 and a 200 day simple moving average of $438.56.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.18 EPS. On average, research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.